1-52032711-G-C

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate

The ENST00000371626.9(TXNDC12):​c.159-4081C>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000172 in 1,455,976 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 0.000017 ( 0 hom. )

Consequence

TXNDC12
ENST00000371626.9 intron

Scores

19

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 3.16
Variant links:
Genes affected
KTI12 (HGNC:25160): (KTI12 chromatin associated homolog) Predicted to enable ATP binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II and tRNA wobble uridine modification. [provided by Alliance of Genome Resources, Apr 2022]
TXNDC12 (HGNC:24626): (thioredoxin domain containing 12) This gene encodes a member of the thioredoxin superfamily. Members of this family are characterized by a conserved active motif called the thioredoxin fold that catalyzes disulfide bond formation and isomerization. This protein localizes to the endoplasmic reticulum and has a single atypical active motif. The encoded protein is mainly involved in catalyzing native disulfide bond formation and displays activity similar to protein-disulfide isomerases. This protein may play a role in defense against endoplasmic reticulum stress. Alternate splicing results in both coding and non-coding variants. [provided by RefSeq, Mar 2012]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 0 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.17309049).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
KTI12NM_138417.3 linkuse as main transcriptc.1051C>G p.Gln351Glu missense_variant 1/1 ENST00000371614.2 NP_612426.1 Q96EK9
TXNDC12NM_015913.4 linkuse as main transcriptc.159-4081C>G intron_variant ENST00000371626.9 NP_056997.1 O95881
TXNDC12NR_046405.1 linkuse as main transcriptn.2574C>G non_coding_transcript_exon_variant 3/3
TXNDC12NR_046406.1 linkuse as main transcriptn.2451C>G non_coding_transcript_exon_variant 3/3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
KTI12ENST00000371614.2 linkuse as main transcriptc.1051C>G p.Gln351Glu missense_variant 1/16 NM_138417.3 ENSP00000360676.1 Q96EK9
TXNDC12ENST00000371626.9 linkuse as main transcriptc.159-4081C>G intron_variant 1 NM_015913.4 ENSP00000360688.4 O95881
ENSG00000285839ENST00000648686.1 linkuse as main transcriptn.640C>G non_coding_transcript_exon_variant 1/7 ENSP00000498140.1 A0A3B3IU88
TXNDC12ENST00000472624.5 linkuse as main transcriptn.159-2163C>G intron_variant 5 ENSP00000477120.1 V9GYV4

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD4 exome
AF:
0.0000172
AC:
25
AN:
1455976
Hom.:
0
Cov.:
33
AF XY:
0.0000166
AC XY:
12
AN XY:
723852
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000216
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
Cov.:
33
Bravo
AF:
0.00000756

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsDec 02, 2022The c.1051C>G (p.Q351E) alteration is located in exon 1 (coding exon 1) of the KTI12 gene. This alteration results from a C to G substitution at nucleotide position 1051, causing the glutamine (Q) at amino acid position 351 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.19
T
BayesDel_noAF
Benign
-0.51
CADD
Benign
22
DANN
Benign
0.97
DEOGEN2
Benign
0.00080
T
Eigen
Benign
-0.40
Eigen_PC
Benign
-0.22
FATHMM_MKL
Benign
0.59
D
LIST_S2
Benign
0.67
T
M_CAP
Benign
0.0065
T
MetaRNN
Benign
0.17
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.1
L
MutationTaster
Benign
1.0
D;D
PrimateAI
Benign
0.33
T
PROVEAN
Benign
-0.50
N
REVEL
Benign
0.037
Sift
Benign
0.19
T
Sift4G
Benign
0.33
T
Polyphen
0.26
B
Vest4
0.21
MutPred
0.28
Gain of catalytic residue at Q351 (P = 0.2407);
MVP
0.51
MPC
0.64
ClinPred
0.64
D
GERP RS
3.7
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.2
Varity_R
0.14
gMVP
0.13

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs377426971; hg19: chr1-52498383; API